Phase 2 Rectal Adenocarcinoma trials recruiting now
All Rectal Adenocarcinoma trials, every phase
8
Phase 2 recruiting
Phase 2 Rectal Adenocarcinoma trials
- A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
- FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
- Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
- The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
- Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
- Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
Common questions
What does Phase 2 mean?
Is this list complete?
No. For the full record, search ClinicalTrials.gov.